Answers are grounded in this paper and cite their sources.
Loss of MSH6 occurred during the progression from an atypical prolactinoma to a pituitary carcinoma, which may have caused resistance to TMZ treatment. This case suggests that preserving MSH6 function is essential for responsiveness to TMZ treatment in MGMT-negative and p53-mutated atypical pituitary adenoma or pituitary carcinoma.
No takes yet. Share an insight, caveat, or question.
Murakami et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: